Evaluation of new gastro-intestinal prokinetic (ENGIP-II) study.
J Indian Med Assoc
;
2005 Dec; 103(12): 708-9
Artículo
en Inglés
| IMSEAR
| ID: sea-96792
ABSTRACT
Non-ulcer dyspepsia is a common clinical disorder characterised by reduced gastric motility. Safety concerns have restricted use of currently available prokinetic drugs. Itopride is a new safer prokinetic drug with dopamine D2 antagonism and acetylcholinesterase inhibitory actions. The ENGIP-II study was conducted to investigate the efficacy, and safety of itopride in patients of non-ulcer dyspepsia. There were significant reductions in upper abdominal pain, heartburn frequency, gastro-oesophageal regurgitation, nausea, bloating, early satiety after meals at day 3 only; whereas significant improvements were noted in belching, anorexia at day 6 and in vomiting at day 9. Thus, ENGIP-II study shows that itopride was well tolerated patients and appears to be the drug of choice in patients with non-ulcer dyspepsia.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Acetilcolinesterasa
/
Seguridad
/
Benzamidas
/
Compuestos de Bencilo
/
Femenino
/
Humanos
/
Masculino
/
Resultado del Tratamiento
/
Receptores de Dopamina D2
/
Adulto
Tipo de estudio:
Ensayo Clínico Controlado
Idioma:
Inglés
Revista:
J Indian Med Assoc
Año:
2005
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS